Palisade Bio Inc.

08/17/2022 | Press release | Distributed by Public on 08/17/2022 06:44

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.